Rite Aid, Payment Alliance International sign ATM deal
LOUISVILLE, Ky. — Drug store chain Rite Aid has picked Payment Alliance International to provide ATM services at about 1,500 of its stores, the ATM network said Monday.
PAI runs ATMs at more than 60,000 retail locations around the country and said that it would offer state-of-the-art equipment, domestic and international transaction processing, and branding opportunities.
"We are thrilled to have such a large and innovative retailer like Rite Aid as a PAI client," PAI president and CEO John Leehy said. "Some of our largest financial institution clients are already abuzz about the potential ATM branding opportunities that will provide their collective customers with surcharge-free access to cash at conveniently located Rite Aid stores."
Reports: Maine law to allow importation of drugs
NEW YORK — A new law in Maine will allow residents of the state to buy drugs through mail-order from licensed pharmacies in other countries, according to published reports.
The Associated Press reported that the law, an amendment to the Maine Pharmacy Act, will allow Mainers to buy drugs through a Canadian mail-order program called CanaRx and licensed programs in the United Kingdom, Australia and New Zealand.
The AP reported that the bill became law without the signature of Gov. Paul LePage and will go into effect in 90 days.
FDA turns down Merck insomnia drug
WHITEHOUSE STATION, N.J. — The Food and Drug Administration has declined to approve a sleeping pill made by Merck & Co., citing issues with dosage.
The drug maker said Monday that it received a complete response letter from the FDA concerning the drug suvorexant, for which it is seeking regulatory approval. A complete response letter means that the agency has finished reviewing its approval application, but questions remain that preclude final approval.
The FDA determined that the drug should be available in a 10-mg dosage, and the 15-mg and 20-mg doses should be given to patients if 10 mg isn’t enough, but based on clinical data, the agency did not think the 30-mg and 40-mg doses would be safe.
"We will evaluate the requests outlined in the complete response letter and expect thereafter to work expeditiously with the FDA to make suvorexant available as a new treatment option for patients suffering from insomnia," Merck Research Labs president Roger Perlmutter said.